AR093457A1 - Derivados de bendamustina y metodos para utilizarlos - Google Patents

Derivados de bendamustina y metodos para utilizarlos

Info

Publication number
AR093457A1
AR093457A1 ARP130104160A ARP130104160A AR093457A1 AR 093457 A1 AR093457 A1 AR 093457A1 AR P130104160 A ARP130104160 A AR P130104160A AR P130104160 A ARP130104160 A AR P130104160A AR 093457 A1 AR093457 A1 AR 093457A1
Authority
AR
Argentina
Prior art keywords
methods
bendamustine
bendamustine derivatives
derivatives
amides
Prior art date
Application number
ARP130104160A
Other languages
English (en)
Inventor
P Bakale Roger
Chen Jian
Y Labell Rachel
R Patel Piyush
d brown Peter
S Drager Anthony
E Mkean Robert
C Roemmele Renee
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of AR093457A1 publication Critical patent/AR093457A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Abstract

La presente se refiere a ésteres y amidas de bendamustina y su utilización para el tratamiento del cáncer. Reivindicación 1: Un compuesto de la fórmula (1) caracterizado porque R¹ es alquilo C₆₋₂₄ o polietilén glicol.
ARP130104160A 2012-11-12 2013-11-12 Derivados de bendamustina y metodos para utilizarlos AR093457A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261725213P 2012-11-12 2012-11-12
US201361776951P 2013-03-12 2013-03-12

Publications (1)

Publication Number Publication Date
AR093457A1 true AR093457A1 (es) 2015-06-10

Family

ID=49667594

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130104160A AR093457A1 (es) 2012-11-12 2013-11-12 Derivados de bendamustina y metodos para utilizarlos

Country Status (17)

Country Link
US (7) US9452988B2 (es)
EP (1) EP2917183A1 (es)
JP (1) JP6262246B2 (es)
KR (1) KR20150086308A (es)
AR (1) AR093457A1 (es)
AU (1) AU2013342015B2 (es)
BR (1) BR112015010501A2 (es)
CA (1) CA2890462A1 (es)
CL (1) CL2015001246A1 (es)
EA (1) EA029706B1 (es)
HK (2) HK1215701A1 (es)
IL (1) IL238662A (es)
MX (1) MX2015005805A (es)
PH (1) PH12015501024A1 (es)
SG (1) SG11201503560TA (es)
TW (1) TWI598341B (es)
WO (1) WO2014075035A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2918588T3 (pl) 2010-05-20 2017-10-31 Array Biopharma Inc Związki makrocykliczne jako inhibitory kinazy TRK
CA2890462A1 (en) * 2012-11-12 2014-05-15 Ignyta, Inc. Bendamustine derivatives and methods of using same
US9598377B2 (en) * 2013-03-12 2017-03-21 Cephalon, Inc. Nanoparticulate and macroparticulate formulations
EA035049B1 (ru) 2015-07-16 2020-04-22 Аррэй Байофарма Инк. СОЕДИНЕНИЯ ЗАМЕЩЕННОГО ПИРАЗОЛО[1,5-a]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ
EP3484519A1 (en) * 2016-07-13 2019-05-22 Cephalon, Inc. Pharmaceutical prodrugs and methods of their preparation and use
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
EP3571203B1 (en) 2017-01-18 2023-06-07 Array BioPharma Inc. Substituted pyrazolo[1,5-a]pyrazine compounds as ret kinase inhibitors
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
TWI812649B (zh) 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
TWI802635B (zh) 2018-01-18 2023-05-21 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡咯并[2,3-d]嘧啶化合物
US11524963B2 (en) 2018-01-18 2022-12-13 Array Biopharma Inc. Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors
JP6997876B2 (ja) 2018-01-18 2022-02-04 アレイ バイオファーマ インコーポレイテッド Ｒｅｔキナーゼ阻害剤としての置換ピラゾリル［４，３－ｃ］ピリジン化合物
CA3224949A1 (en) 2018-07-31 2020-02-06 Loxo Oncology, Inc. Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide
CA3111984A1 (en) 2018-09-10 2020-03-19 Array Biopharma Inc. Fused heterocyclic compounds as ret kinase inhibitors

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681964A (en) * 1990-10-23 1997-10-28 University Of Kentucky Research Foundation Permeable, non-irritating prodrugs of nonsteroidal and steroidal agents
US5834025A (en) 1995-09-29 1998-11-10 Nanosystems L.L.C. Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
US7089218B1 (en) 2004-01-06 2006-08-08 Neuric Technologies, Llc Method for inclusion of psychological temperament in an electronic emulation of the human brain
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
WO2002043663A2 (en) 2000-12-01 2002-06-06 Enzon, Inc. Tetrapartate prodrugs
AU2003227147A1 (en) * 2002-04-05 2003-10-27 Universite De Montreal Stealthy polymeric biodegradable nanospheres and uses thereof
HUE040046T2 (hu) 2002-12-09 2019-02-28 Abraxis Bioscience Llc Gyógyszerészeti készítmények és hatóanyagok beadására szolgáló eljárások
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
EP1853250B1 (en) 2005-02-18 2011-11-02 Abraxis BioScience, LLC Combinations and modes of administration of therapeutic agents and combination therapy
DE102005062440B4 (de) * 2005-12-27 2011-02-24 Lts Lohmann Therapie-Systeme Ag Proteinbasiertes Trägersystem zur Resistenzüberwindung von Tumorzellen
KR101563658B1 (ko) * 2007-11-28 2015-10-27 셀라토 파마슈티칼즈, 인코포레이티드 개선된 탁산 전달 시스템
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
CN104224703A (zh) 2008-09-25 2014-12-24 赛福伦公司 苯达莫司汀的液体配制品
US9149441B2 (en) * 2008-09-29 2015-10-06 The Corporation Of Mercer University Nanospheres encapsulating bioactive material and method for formulation of nanospheres
JP5773874B2 (ja) * 2008-10-08 2015-09-02 セファロン、インク． ベンダムスチンの調製方法
UA102120C2 (ru) * 2008-12-03 2013-06-10 Астеллас Дойчленд Гмбх Пероральная форма дозирования бендамустина
WO2011151087A1 (en) 2010-06-02 2011-12-08 Astellas Deutschland Gmbh Oral dosage forms of bendamustine
TWI578997B (zh) 2010-06-04 2017-04-21 輝瑞疫苗有限責任公司 用於預防或治療菸鹼成癮之共軛體
CN101966158A (zh) 2010-09-28 2011-02-09 上海丽思化工科技有限公司 一种注射用盐酸苯达莫司汀冻干粉针剂及其制备方法
EP2635558A4 (en) 2010-11-01 2014-08-06 Shilpa Medicare Ltd PROCESS FOR PREPARING BENDAMUSTINE HYDROCHLORIDE MONOHYDRATE
DE102010055499A1 (de) * 2010-12-22 2011-06-16 W.C. Heraeus Gmbh Prozess zur Herstellung von Bendamustinalkylester, Bendarmustin sowie Derivaten davon
US9427477B2 (en) 2011-05-09 2016-08-30 Mayo Foundation For Medical Education And Research Cancer treatments
US9308276B2 (en) 2011-05-17 2016-04-12 University Of South Alabama Combination therapy for treatment of cancer
WO2013046223A1 (en) 2011-09-26 2013-04-04 Fresenius Kabi Oncology Ltd. An improved process for the preparation of bendamustine hydrochloride
DK2656843T3 (en) 2012-04-26 2015-04-20 Helmut Schickaneder Esters of bendamustine and related compounds, and medical use thereof
RU2695383C2 (ru) 2012-06-19 2019-07-23 Синбиас Фарма АГ Производные бендамустина, родственные соединения и их медицинское применение для лечения рака
US9314532B2 (en) 2012-08-10 2016-04-19 University Of North Texas Health Science Center Drug delivery vehicle
CA2890462A1 (en) * 2012-11-12 2014-05-15 Ignyta, Inc. Bendamustine derivatives and methods of using same

Also Published As

Publication number Publication date
IL238662A (en) 2017-08-31
JP2015536996A (ja) 2015-12-24
MX2015005805A (es) 2016-04-15
PH12015501024A1 (en) 2015-07-27
US20160289198A1 (en) 2016-10-06
SG11201503560TA (en) 2015-06-29
US9149464B2 (en) 2015-10-06
EP2917183A1 (en) 2015-09-16
TWI598341B (zh) 2017-09-11
US20150274675A1 (en) 2015-10-01
TW201439069A (zh) 2014-10-16
HK1212977A1 (zh) 2016-06-24
AU2013342015B2 (en) 2016-11-24
US20160016912A1 (en) 2016-01-21
US20150246023A1 (en) 2015-09-03
EA029706B1 (ru) 2018-05-31
BR112015010501A2 (pt) 2017-07-11
CN105051016A (zh) 2015-11-11
EA201590925A1 (ru) 2015-09-30
JP6262246B2 (ja) 2018-01-17
US9150517B2 (en) 2015-10-06
US20170182008A1 (en) 2017-06-29
WO2014075035A1 (en) 2014-05-15
IL238662A0 (en) 2015-06-30
US9630926B2 (en) 2017-04-25
KR20150086308A (ko) 2015-07-27
US20180147186A1 (en) 2018-05-31
CL2015001246A1 (es) 2016-01-15
US20150232427A1 (en) 2015-08-20
CA2890462A1 (en) 2014-05-15
US9913827B2 (en) 2018-03-13
US9452988B2 (en) 2016-09-27
AU2013342015A1 (en) 2015-05-28
HK1215701A1 (zh) 2016-09-09

Similar Documents

Publication Publication Date Title
AR093457A1 (es) Derivados de bendamustina y metodos para utilizarlos
CY1122266T1 (el) Ενωσεις 3-αμινοκυκλοαλκυλιου ως ror-gamma-t αναστολεις και χρησεις αυτων
PH12019501197A1 (en) Therapeutically active compounds and their methods of use
CL2017002483A1 (es) Compuestos heterocíclicos como inhibidores de lsd1
CL2015003395A1 (es) Derivados pirazolopirrolidina y su uso en el tratamiento de la enfermedad
ECSP15026557A (es) Compuestos y sus métodos de empleo
CR20210079A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
CR20150571A (es) Compuestos y composiciones terapéuticos
IL240673B (en) Synthesis and Composition of Conjugated Amino Acid Binding Groups for Compounds Used for Targeted Imaging of Tumors
ECSP14012726A (es) Compuestos terapéuticamente activos y sus métodos de uso
CO7350620A2 (es) Nuevos derivados de piridina
CR20150078A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
UY35898A (es) ?compuestos inhibidores de syk y composiciones que los comprenden?.
CR20150447A (es) Nuevos derivados de pirazol
CR20140468A (es) Inhibidores de diacilglicerol aciltransferasa 2
UY34523A (es) Derivados de betulina
SV2016005279A (es) Inhibidores de diacilglicerol aciltransferasa 2
CR20150470A (es) Derivados de triazolona de piridinilo y piridinilo fusionado
UY33884A (es) Inhibición de la il17 y del ifn-gamma para el tratamiento de las inflamaciones autoinmunes
UY34538A (es) Heteroarilos y usos de los mismos
CR20140528A (es) Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de Bace1
IN2014DN10214A (es)
MX2016006975A (es) Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias.
PE20151669A1 (es) Compuestos de azetidiniloxifenilpirrolidina
PE20150674A1 (es) Azaheterociclos como inhibidores de bir2 y/o bir3

Legal Events

Date Code Title Description
FB Suspension of granting procedure